Company

TAKEDA PHARMACEUTICAL CO LTD (TAK)

Standardized SEC financial data for TAKEDA PHARMACEUTICAL CO LTD — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001395064 · NYSE · Pharmaceutical Preparations.

Gross margin

65.5%

Net margin

2.4%

Revenue growth (YoY)

7.5%

Return on equity

1.6%

Ratios for fiscal year 2025, standardized from SEC filings.

Income statement

¥	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	¥3291.19B	¥3197.81B	¥3569.01B	¥4027.48B	¥4263.76B	¥4581.55B
Cost of revenue	¥1089.76B	¥994.31B	¥1106.85B	¥1244.07B	¥1426.68B	¥1580.22B
Gross profit	¥2201.42B	¥2203.50B	¥2462.16B	¥2783.41B	¥2837.08B	¥3001.33B
R&D expense	¥492.38B	¥455.83B

Standardized from TAKEDA PHARMACEUTICAL CO LTD's SEC filings — per-share figures split-adjusted. Full history via the API.

Balance sheet

¥	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Goodwill	¥4012.53B	¥4033.92B	¥4407.75B	¥4790.72B	¥5410.07B	¥5324.43B
Total assets	¥12821.09B	¥12912.29B	¥13178.02B	¥13957.75B	¥15108.79B	¥14248.34B
Total liabilities	¥8093.61B	¥7735.12B	¥7494.49B	¥7603.08B

Get TAK data via API

# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/TAK/financials \
  -H "X-API-Key: YOUR_KEY"

# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/TAK/income-statement?format=csv" \
  -H "X-API-Key: YOUR_KEY"

Get a free API key Use with Claude (MCP) →View TAK filings on SEC EDGAR →